As one of the genes that have been investigated more thoroughly in breast cancer to date, HER2 overexpression is not only linked to the occurrence and development of tumors, but also an ideal clinical treatment monitoring and prognostic indicator, and a specific drug candidate for tumor-targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.